Anthropic reveals it is developing its own experimental drugs using Claude, targeting rare childhood diseases and cancers
Polymarket · x · 2026-10-28
Per a Polymarket breaking post, Anthropic has disclosed it is developing its own experimental drugs with Claude, targeting rare childhood diseases and various cancers — a notable move into in-house drug discovery rather than only supplying models to pharma partners.
Related event: Anthropic Uses Claude to Develop Its Own Experimental Drugs(2 posts)→
More from Companies & People
- Economist Bharat Chandar named Research Director for AI Economics at DigEconLab — soumitrashukla9 · 2026-10-28
- AI support cuts keep getting reversed: Gartner's 14% self-service success rate explains why — Nir777 · 2026-10-28
- Peter Diamandis: Only Founders Obsessed With a Problem for a Decade Should Start Companies — PeterDiamandis · 2026-10-28
- Anthropic Acquires One-Person Biotech Startup That Used Claude to Coordinate 11 Labs — Polymarket · 2026-10-28
- Computer scientist on being interviewed by an "AI Reporter": honesty made it fine — fortnow · 2026-10-28
- Google brings Gemini Robotics ER 2 embodied reasoning model to Google Cloud — ZoubinGhahrama1 · 2026-10-28